Loading clinical trials...
Loading clinical trials...
Pilot Study of Raltegravir, an Integrase Inhibitor, in Human T-Cell Lymphotrophic Virus-1(HTLV-1) Associated Myelopathy, Tropical Spastic Paraparesis (HAM/TSP)
Conditions
Interventions
Raltegravir
Locations
1
United States
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Start Date
September 5, 2013
Primary Completion Date
September 25, 2018
Completion Date
September 25, 2018
Last Updated
March 30, 2023
NCT00001778
NCT03829709
NCT00001941
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions